To target or not to target APRIL in systemic lupus erythematosus: that is the question!
1 Department of Rheumatology, CHU Lapeyronie, 191 Avenue du Doyen Gaston, Giraud, 34295 Montpellier, Cedex 5, France
2 Institut de Génétique Moléculaire de Montpellier, CNRS, UMR5535, 1919 route de Mende, 34293 Montpellier, France
3 Université Montpellier 1, 5 Boulevard Henri IV, 34000 Montpellier, Cedex 5, France
4 Université Montpellier 2, Place Eugène Bataillon, 34095 Montpellier, Cedex 5, France
Citation and License
Arthritis Research & Therapy 2013, 15:107 doi:10.1186/ar4160
See related research by Treamtrakanpon et al., http://arthritis-research.com/content/14/6/R252Published: 25 February 2013
Among the cytokines that regulate B-cell homeostasis are the TNF-like ligands B-lymphocyte stimulator (BLyS; also B-cell activation factor) and a proliferation-inducing ligand (APRIL). BLyS and APRIL share two receptors; that is, B-cell maturation antigen and transmembrane activator and CAML interactor. Therapeutic approaches using biologics are limited for treatment of lupus patients. One previously approved drug is belimumab, which antagonizes the B-cell stimulator BLyS. Atacicept, another biologic inhibiting BLyS and APRIL, was terminated for serious adverse events - raising the question of whether APRIL should be neutralized in autoimmune diseases.